Financière de Tubize – Annual report 2023
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: [email protected] Annual Report 2023 Regulated information16 March 2024…
Pharmaceuticals, Biotechnology and Life Sciences
FINANCIERE DE TUBIZE SA/NV Allée de la Recherche 60, 1070 Brussels Contact: [email protected] Annual Report 2023 Regulated information16 March 2024…
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM) announced that on March 11,…
TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (Germany: J90) (the “Company” or…
SAN JOSE, Calif., March 15, 2024 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a…
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis…
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code…
The certification has the potential to open access to Islamic markets globally, expanding potential markets for Scilex’s innovative FDA approved…
NEW YORK, March 15, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a…
SAN DIEGO, March 15, 2024 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the…
PALO ALTO, Calif., March 15, 2024 (GLOBE NEWSWIRE) — Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue…